Safe administration of yellow fever vaccine in patients with suspected egg allergy

BACKGROUND: The evidence available in the literature on the administration and safety of the yellow fever vaccine in patients with egg allergy is limited. OBJECTIVE: We sought to describe the administration of yellow fever vaccine in children with suspected egg allergy using a simplified protocol. METHODS: Children referred to the service from February 2018 to January 2020 with a history of possible egg allergy were classified as probably egg-allergic or not on the basis of history and specific IgE testing. A vaccine prick test was performed only in those with a history of an anaphylactic reaction to egg ingestion and if the result was positive the vaccine was administered in a 2-step protocol (2 equal doses of 0.25 mL with an interval of 30 minutes between the 2 applications). All other children received the vaccine as a single dose. RESULTS: A total of 435 children were evaluated; 48.27% were probably not allergic, and 51.72% were probably allergic to egg, of which 32.88% were considered anaphylactic. A total of 414 (95.2%) children had no vaccine reactions. Of the 21 (4.8%) children who had some reaction, 10 experienced a local reaction, 9 a mild skin reaction distant from the vaccine site, 1 presented local cutaneous reaction distant to the vaccination site, and 1 patient developed possible anaphylaxis. The vaccine prick test did not predict a vaccine reaction (odds ratio, 1.29; 95% CI, 0.25-6.72; P = .67). CONCLUSIONS: Yellow fever vaccine can be safely administered as a single dose in children with a confirmed or suspected egg allergy.